Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(53)
•••
Post by waves1on Feb 21, 2023 2:11pm
122 Views
Post# 35296777

AGN expands psychedelic portfolio w/ DMT for TBI study

AGN expands psychedelic portfolio w/ DMT for TBI study

AGN continuing to expand its psychedelic portfolio with the addition of a new clinical research program for the treatment of TBI with DMT!

Using the data from its Phase 1 Study of DMT for Stroke, AGN is able to accelerate to a Phase 2 clinical trial planned for Q4 2023 and AGN will be the first company globally to investigate DMT for TBI in humans.

As the global TBI market is projected to grow from USD $3.1 billion in 2021 to USD $4.5 billion by 2026 at CAGR of 8.0%, this is a significant market opportunity for AGN
https://www.globenewswire.com/news-release/2023/02/21/2611945/0/en/Algernon-NeuroScience-Initiates-Traumatic-Brain-Injury-Research-Program-With-DMT-Appoints-Global-TBI-Expert-as-Advisor.html 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities